Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from CellaVision AB ( (SE:CEVI) ) is now available.
CellaVision AB will publish its year-end report for 2025 on 5 February 2026 and make it available on the company’s website, followed by an English-language conference call and webcast at 11:00 CET where President and CEO Simon Østergaard will present and comment on the results. The event is aimed at analysts, investors and media, reflects the company’s ongoing commitment to transparent financial communication, and gives stakeholders an opportunity to engage directly with management on CellaVision’s performance and outlook in the medical diagnostics technology market.
The most recent analyst rating on (SE:CEVI) stock is a Hold with a SEK166.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.
More about CellaVision AB
CellaVision AB is a global medical technology company specializing in automated systems for routine analysis of blood and other body fluids used in healthcare diagnostics. Its products, which leverage expertise in sample preparation, image analysis, artificial intelligence and automated microscopy, aim to replace manual laboratory work and streamline workflows across hospitals. The company sells primarily through global partners and 12 local market support organizations covering more than 40 countries, generated SEK 723 million in sales in 2024, targets 15% annual growth over an economic cycle, and is listed on Nasdaq Stockholm’s Mid Cap list.
Average Trading Volume: 27,068
Technical Sentiment Signal: Sell
Current Market Cap: SEK3.77B
For an in-depth examination of CEVI stock, go to TipRanks’ Overview page.